New EASL Guidelines Aim to Improve Diagnostic Accuracy and Outcomes for AIH Patients
The European Association for the Study of the Liver (EASL) has published new guidelines for the diagnosis and management of autoimmune hepatitis (AIH) both in children and adults. These EASL Clinical Practice Guidelines bring substantial revisions to the previous 2015 edition and reflect recent evidence and expert consensus aimed at improving diagnostic accuracy and enhancing therapeutic outcomes across the wide clinical spectrum of the disease. The updated recommendations reference two publications featuring the participation of two PSI medical monitors.
“These new guidelines pose Tacrolimus as a potential third-line rescue therapy in difficult-to-treat patients, those nonresponders to first-line treatments or those who need to discontinue due to side effects of long-term use of those.”
”These guidelines recommend an early treatment with corticosteroids in patients with acute severe AIH without acute liver failure (ALF) or acute on chronic liver failure (ACLF). They also suggest evaluating response to treatment between days 3 and 7. Failure to respond to steroids at that timepoint should trigger referral to a liver transplantation (LT) center. Additionally, predictors of poor outcome are highlighted.”
Some of the primary updates in the new guidelines include:
Diagnosis:
Removal of recommendations to subclassify AIH based on autoantibody profiles.
Incorporation of criteria proposed by the International Autoimmune Hepatitis Pathology Group to support more consistent and standardised interpretation of liver biopsies, which remain a cornerstone of AIH diagnosis.
Utilization of the Enhanced Liver Fibrosis (ELF) test, Fibrosis-4 index (FIB-4), and NAFLD Fibrosis Score as non-invasive tests to aid in early diagnosis and reevaluation of liver disease.
Treatment:
Removal of recommendation of Budesonide; first-line therapy continues to be corticosteroids, tailored to disease severity and patient tolerance.
Extension of the timepoint to evaluate response to a broader window of 6 to 12 months.
Recommendation of alternative immunosuppressive agents for patients intolerant or unresponsive to standard therapy.
Specific recommendations for effective treatment and long-term management for pediatric patients, including guidance for those under six years old and children with AIH/primary sclerosing cholangitis (PSC) overlap syndromes.
Monitoring and Management:
Recommendation of regular monitoring of liver function tests and immunoglobulin levels to assess treatment response and detect relapses early.
Incorporation of strategies for managing AIH variants and overlap syndromes, as well as considerations for pediatric and elderly populations.
The recent EASL guidelines mark a significant advancement in the diagnosis and management of autoimmune hepatitis, providing healthcare professionals with the tools needed to improve patient outcomes. With expert insights from PSI’s medical monitors, these guidelines emphasize the importance of early intervention and tailored treatment strategies. If you want to delve deeper into how PSI’s expertise in gastroenterology clinical trials can enhance your understanding and application of these guidelines, we invite you to connect with our team.
New EASL Guidelines Aim to Improve Diagnostic Accuracy and Outcomes for AIH Patients
The European Association for the Study of the Liver (EASL) has published new guidelines for the diagnosis and management of autoimmune hepatitis (AIH) both in children and adults. These EASL Clinical Practice Guidelines bring substantial revisions to the previous 2015 edition and reflect recent evidence and expert consensus aimed at improving diagnostic accuracy and enhancing therapeutic outcomes across the wide clinical spectrum of the disease. The updated recommendations reference two publications featuring the participation of two PSI medical monitors.
“Tacrolimus as an Effective and Durable Second-Line Treatment for Chronic Autoimmune Hepatitis: A Multicentric Study” in Digestive Diseases and Sciences features contributions from Carlos Ferre, Senior Medical Monitor at PSI Spain. Eugenia Sanchez, Medical Monitor at PSI Spain, contributed to “Early Predictors of Corticosteroid Response in Acute Severe Autoimmune Hepatitis: A Nationwide Multicenter Study” in Alimentary Pharmacology and Therapeutics., a paper based on her PhD research.
Some of the primary updates in the new guidelines include:
The recent EASL guidelines mark a significant advancement in the diagnosis and management of autoimmune hepatitis, providing healthcare professionals with the tools needed to improve patient outcomes. With expert insights from PSI’s medical monitors, these guidelines emphasize the importance of early intervention and tailored treatment strategies. If you want to delve deeper into how PSI’s expertise in gastroenterology clinical trials can enhance your understanding and application of these guidelines, we invite you to connect with our team.
Share